Case report · 2023
Research articlePublished 20 Jun 2022
Evaluation of Microparticulate Cytokine Inhibitors for their Potential Use for the Treatment of COVID-19 Cytokine Storm
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
COVID-19 pandemic has claimed millions of lives and resulted in an economic slowdown worldwide. The mortality rate is approximately 2% in the United States, with many individuals requiring prolonged hospitalization. At least 10% of patients with severe COVID-19 will eventually have respiratory failure. The recent deployment of a vaccine will hopefully ease and ultimately deter the spread of this highly contagious virus. However, newer virulent strains continue to emerge since most people in different parts of the world have little or no access to vaccines. The virus is associated with the cytokine storm in its severe form. This manifestation is highly lethal, resulting in acute respiratory distress syndrome and multi-organ failure. Since only a few therapeutic drugs can treat severe COVID-19, it is essential to focus on therapeutic strategies to increase the COVID-19 survival rate and preventive vaccination. This review describes microparticulate cytokine inhibiting agents such as antisense oligonucleotides to Nuclear Factor kappa B (NF-kB), antioxidant, catalase, Tumor necrosis factor (TNF) and Interleukin-1 (IL-1) neutralizing antibodies, CNI-1493 and dexamethasone. These microparticulate cytokine inhibiting agents have demonstrated remarkable effectiveness in cytokine suppression intracellularly compared to equivalent drug doses in solution. Much of this work was published before the emergence of COVID-19 and its subsequent variants. Moreover, these microparticles might effectively moderate cytokine storms and requires additional review and investigation.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Research article · 12 Feb 2021
Prophylactic administration of a clinically safe low dose of the COVID-19 drug candidate Rejuveinix (RJX) effectively prevents fatal cytokine storm and mitigates inflammatory organ injury in a mouse model of sepsis
Case report · 31 Jul 2024
COVID-19 Associated Cytokine Storm: A Double Edged Sword of Sustained Protection for Some Survivors or a Deadly Outcome for Many
Research article · 27 Jul 2020
The Values of Cytokines in Evaluating the Severity and Prognosis of COVID-19
Research article · 29 Jan 2021
Detection of Lymphocyte Subsets and Inflammatory Cytokines in Mild and Severe COVID-19 Patients
More from this journal
The newest in Translational Medicine.
Opinion · 25 Jun 2026
Radiomics in Translational Medicine for Quantitative Imaging and Personalized Clinical Assessment
Opinion · 25 Jun 2026
Digital Twin Technology in Translational Medicine for Individualized Disease Simulation and Clinical Planning
Opinion · 25 Jun 2026
Proteomic Signatures in Translational Medicine for Disease Stratification and Therapeutic Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Mohammad N. Uddin”
- BylineArticles whose byline prints “Priyal Bagwe”
- BylineArticles whose byline prints “Carl Oettinger”
- BylineArticles whose byline prints “Martin J. D'Souza”

